OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp is positioned to capitalize on the ongoing shift from in-person to digital interactions within the healthcare market, anticipating revenue growth in the high teens to low twenties while expanding its margins. The company’s current workforce is capable of supporting a revenue run-rate of approximately $150 million, indicating significant operating leverage over the next two to three years. With a gross margin of 74.8% bolstered by an advantageous channel partner mix, along with record AEBITDA of $12 million, OptimizeRx demonstrates strong cost management and broad adoption of its services, reinforcing a positive long-term growth outlook.

OptimizeRx Corp has revised its 2026 revenue guidance downwards from $118M-$124M to $109M-$114M, indicating significant near-term challenges as the company anticipates revenue decline in the first half of 2026 due to reduced spending from large pharma clients amid the "most favored nation" pricing initiative. The company also reported a deterioration in net revenue retention, falling 400-500 basis points year-over-year, which reflects the broader industry struggles and suggests a weakening demand for its services. Additionally, the visibility into future revenues is noted to be 15-20% lower than at the beginning of 2025, compounding concerns about the company's ability to stabilize growth and maintain profitable operations in the near term.